Idioma:

Identification of prognostic markers in diffuse midline gliomas H3K27M‐mutant

Dufour, Charlotte ; Perbet, Romain ; Leblond, Pierre ; Vasseur, Romain ; Stechly, Laurence ; Pierache, Adeline ; Reyns, Nicolas ; Touzet, Gustavo ; Le Rhun, Emilie ; Vinchon, Matthieu ; Maurage, Claude‐Alain ; Escande, Fabienne ; Renaud, Florence

Brain pathology (Zurich, Switzerland), 2020-01, Vol.30 (1), p.179-190 [Periódico revisado por pares]

Switzerland: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Identification of prognostic markers in diffuse midline gliomas H3K27M‐mutant
Autor: Dufour, Charlotte ; Perbet, Romain ; Leblond, Pierre ; Vasseur, Romain ; Stechly, Laurence ; Pierache, Adeline ; Reyns, Nicolas ; Touzet, Gustavo ; Le Rhun, Emilie ; Vinchon, Matthieu ; Maurage, Claude‐Alain ; Escande, Fabienne ; Renaud, Florence
Assuntos: Amplification ; chomosomal profile ; diffuse midline gliomas ; Epidermal growth factor receptors ; H3K27M‐mutant ; Hybridization ; Immunohistochemistry ; Life Sciences ; Markers ; Medical prognosis ; molecular alterations ; Mutation ; p53 Protein ; Patients ; Prognosis ; prognostic markers ; Subgroups ; Survival ; translational study ; Tumors
É parte de: Brain pathology (Zurich, Switzerland), 2020-01, Vol.30 (1), p.179-190
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Pediatric diffuse midline gliomas are devastating diseases. Among them, diffuse midline gliomas H3K27M‐mutant are associated with worse prognosis. However, recent studies have highlighted significant differences in clinical behavior and biological alterations within this specific subgroup. In this context, simple markers are needed to refine the prognosis of diffuse midline gliomas H3K27M‐mutant and guide the clinical management of patients. The aims of this study were (i) to describe the molecular, immunohistochemical and, especially, chromosomal features of a cohort of diffuse midline gliomas and (ii) to focus on H3K27M‐mutant tumors to identify new prognostic markers. Patients were retrospectively selected from 2001 to 2017. Tumor samples were analyzed by immunohistochemistry (including H3K27me3, EGFR, c‐MET and p53), next‐generation sequencing and comparative genomic hybridization array. Forty‐nine patients were included in the study. The median age at diagnosis was 9 years, and the median overall survival (OS) was 9.4 months. H3F3A or HIST1H3B mutations were identified in 80% of the samples. Within the H3K27M‐mutant tumors, PDGFRA amplification, loss of 17p and a complex chromosomal profile were significantly associated with worse survival. Three prognostic markers were identified in diffuse midline gliomas H3K27M‐mutant: PDGFRA amplification, loss of 17p and a complex chromosomal profile. These markers are easy to detect in daily practice and should be considered to refine the prognosis of this entity.
Editor: Switzerland: Wiley Subscription Services, Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Identification of prognostic markers in diffuse midline gliomas H3K27M‐mutant

Dufour, Charlotte ; Perbet, Romain ; Leblond, Pierre ; Vasseur, Romain ; Stechly, Laurence ; Pierache, Adeline ; Reyns, Nicolas ; Touzet, Gustavo ; Le Rhun, Emilie ; Vinchon, Matthieu ; Maurage, Claude‐Alain ; Escande, Fabienne ; Renaud, Florence

Switzerland: Wiley Subscription Services, Inc

Buscando em bases de dados remotas. Favor aguardar.